Search
for
Sort by
Research 30 of 1000+
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- JAK inhibition decreases the autoimmune burden in Down syndrome
- APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report